One plan - full access

No subscription, no auto-renewal, no hidden terms.
Pay once and use it for 30 days.

PRO plan No auto-renewal
$18

30 days of full access
One-time payment

🌐 US & Global Companies
Get access for 30 days →
♧ Secure payment · Instant access

What is included

  • ✓Full access to detailed company analysis
  • ✓Fundamental screener
  • ✓Advanced stock screener filters
  • ✓5 ratings. Separate lists for US & Global Companies and MOEX
  • ✓Company data export in XLSX and CSV
  • ✓MarketCap’s overall ranking of top companies
  • ✓Analytics updates after each new financial report
⚠ The service is not an investment advisor. Financial statement data from public companies is available to everyone - MarketCap structures and analyzes it.
Liquidia Corporation logo
Liquidia Corporation LQDA
$ 44.26 7.4%
report update icon

Quarterly report 2026-Q2
added 08-12-2026

Liquidia Corporation Financial Statements 2025-2011 | LQDA

Annual Financial Statements Liquidia Corporation

2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

Market Cap

2.95 B 2.7 B 957 M 440 M 242 M 103 M 105 M 98.9 M - - - - - - -

Shares

86.1 M 78.7 M 65 M 61 M 49.7 M 37.8 M 18.5 M 7.16 M - - - - - - -

Historical Prices

34.2 34.2 14.7 7.22 4.87 2.95 4.28 21.7 - - - - - - -

Net Income

-68.9 M -130 M -78.5 M -41 M -34.6 M -59.8 -47.6 M -53.1 M -29.2 M -15.9 M - - - - -

Revenue

158 M 14 M 17.5 M 15.9 M 12.9 M 0.74 8.07 M 2.71 M 7.26 M 13.2 M - - - - -

Cost of Revenue

- 5.88 M 2.89 M 2.86 M 3.02 M 238 K - - - - - - - - -

Gross Profit

- - - - - 0.502 7.26 M 2.59 M 6.94 M 12.3 M - - - - -

Operating Income

-51.4 M -121 M -73.4 M -38.8 M -33.8 M -59.1 M -46.8 M - - - - - - - -

Interest Expense

- - 6.27 M 2.34 M 762 K 858 K 1.37 M - - - - - - - -

EBITDA

-49.8 M -119 M -71.2 M -35.1 M -28.2 M 3.07 K -44.3 M -33.3 M -27.1 M -15.2 M - - - - -

Operating Expenses

- - - - - 59.6 54.1 M 37.5 M 35 M 28.2 M - - - - -

General and Administrative Expenses

157 M 81.6 M 44.7 M 32.4 M 23.1 M 27.4 M 13.6 M 8.75 M 10.2 M 4.84 M - - - - -

All numbers in USD currency

Quarterly Income Statement Liquidia Corporation

2026-Q2 2026-Q1 2025-Q4 2025-Q3 2025-Q2 2025-Q1 2024-Q4 2024-Q3 2024-Q2 2024-Q1 2023-Q4 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Shares

85.6 M 88 M - 86.3 M 85.6 M 85.2 M 84.7 M 78.3 M 76.4 M 75.4 M 68.6 M 64.9 M 64.8 M 64.7 M 64.5 M 64.5 M 62.2 M 52.5 M 52.3 M 52.1 M 50.8 M 43.4 M 43.3 M 37.8 M 28.5 M 28.4 M 28.2 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Net Income

-38.4 M 52.9 M - -3.53 M -41.6 M -38.4 M - -31 M -28.7 M -30.1 M - -15.8 M -23.5 M -11.7 M - -9.09 M -9.45 M -15.9 M - -7.28 M -6.55 M -9.18 M - -15 M -13.9 M -14.8 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Revenue

8.84 M 133 M - 54.3 M 8.84 M 3.12 M - 4.45 M 3.66 M 2.97 M - 3.68 M 4.79 M 4.49 M - 3.16 M 3.92 M 3.49 M - 3.18 M 3.38 M 3.08 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Cost of Revenue

- - - - - 1.52 M - 1.56 M 1.49 M 1.47 M - 570 K 671 K 654 K - 740 K 731 K 694 K - 890 K 714 K 694 K - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Operating Income

-37.5 M 61.5 M - 1.77 M -37.5 M -35.4 M - -29.2 M -27.2 M -28.8 M - -14.9 M -22.8 M -9.23 M - -8.83 M -8.97 M -14.5 M - -7.08 M -6.35 M -9 M - -14.8 M -13.7 M -14.6 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Interest Expense

- - - - - - - 3 M 2.6 M 2.52 M - 1.76 M 1.43 M 1.12 M - 620 K 542 K 478 K - 205 K 203 K 150 K - 191 K 211 K 255 K - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

EBITDA

-37.4 M 62 M - 2.07 M -37.3 M -35 M - -28.9 M -27 M -28.3 M - -14.6 M -22.5 M -8.66 M - -8.43 M -8.57 M -13.5 M - -2.34 M -3.16 M -7.39 M - -12.6 M -12.3 M -13.9 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

General and Administrative Expenses

38.8 M 46.9 M - 40.1 M 38.8 M 30.1 M - 20.2 M 19.9 M 20.2 M - 10.6 M 9.24 M 7.79 M - 6.74 M 6.94 M 12.5 M - 4.88 M 4.42 M 5.34 M - 7.15 M 5.23 M 3.82 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

All numbers in USD currency

Financial statements are the primary tool companies use to inform stakeholders about their financial position, performance, and changes in capital structure. It is a kind of "business language" understood by investors, creditors, tax authorities, and other participants in the economic environment.

Main types of financial statements Liquidia Corporation LQDA
  1. Income Statement
    Shows income, expenses, and resulting profit or loss over a specific period. Helps assess business profitability.
  2. Balance Sheet
    Reflects a company’s assets, liabilities, and equity as of a specific date. It’s a snapshot of what the company owns and owes.
    Assets — everything the company owns (cash, equipment, buildings, accounts receivable, etc.).
    Liabilities — debts and other external sources of financing.
    Equity — owners' capital and retained earnings.
  3. Cash Flow Statement
    Reveals how the company earns and spends money in three areas: operating, investing, and financing activities.
International reporting standards
  • IFRS — International Financial Reporting Standards, applicable to public and multinational companies.
  • GAAP — Generally Accepted Accounting Principles used in the United States.
  • RAS — Russian Accounting Standards, used domestically in Russia.

Financial reporting Liquidia Corporation plays a crucial role for investors as it serves as an objective source of information about a company's current state. Based on the reports, one can determine whether a company is growing, stagnating, or losing market share. This allows investors to identify both promising and problematic assets in a timely manner.

In addition, financial data provides a basis for forecasting future returns. Historical trends in revenue, profit, and cash flow help evaluate potential dividends, the likelihood of stock price growth, and overall investment risk.

Transparent and accurate reporting is also an indicator of a company’s maturity and managerial responsibility. Such openness builds investor confidence and simplifies investment decision-making, especially when comparing multiple companies.

Finally, financial statements enable high-quality comparative analysis. They allow companies to be evaluated against each other in terms of profitability, debt levels, margins, and other key metrics — which is particularly important when choosing the best investment options within an industry or market segment.

Financial statements of other stocks in the Biotechnology industry

Issuer Price % 24h Market Cap Country
Brickell Biotech Brickell Biotech
BBI
- -5.38 % $ 6.06 M usaUSA
Applied Therapeutics Applied Therapeutics
APLT
- - $ 8.42 M usaUSA
ESSA Pharma ESSA Pharma
EPIX
- - $ 8.86 M canadaCanada
Generation Bio Co. Generation Bio Co.
GBIO
- - $ 344 M usaUSA
Clearside Biomedical Clearside Biomedical
CLSD
- - $ 25.3 M usaUSA
Merus N.V. Merus N.V.
MRUS
- - $ 5.78 B niderlandNiderland
RAPT Therapeutics RAPT Therapeutics
RAPT
- - $ 2.36 B usaUSA
Exicure Exicure
XCUR
$ 1.05 -1.85 % $ 6.61 M usaUSA
Cellectis S.A. Cellectis S.A.
CLLS
$ 0.99 0.69 % $ 99.3 M franceFrance
AbCellera Biologics AbCellera Biologics
ABCL
$ 12.16 2.88 % $ 3.63 B canadaCanada
Arrowhead Pharmaceuticals Arrowhead Pharmaceuticals
ARWR
$ 59.01 1.7 % $ 7.89 B usaUSA
BioMarin Pharmaceutical BioMarin Pharmaceutical
BMRN
$ 55.56 -0.7 % $ 10.7 B usaUSA
Celldex Therapeutics Celldex Therapeutics
CLDX
$ 29.4 0.5 % $ 1.95 B usaUSA
CollPlant Biotechnologies Ltd. CollPlant Biotechnologies Ltd.
CLGN
$ 3.78 3.0 % $ 46.1 M israelIsrael
Jaguar Health Jaguar Health
JAGX
$ 2.34 14.46 % $ 5.46 M usaUSA
Protalix BioTherapeutics Protalix BioTherapeutics
PLX
$ 2.49 -2.55 % $ 196 M israelIsrael
uniQure N.V. uniQure N.V.
QURE
$ 22.07 -1.6 % $ 1.27 B niderlandNiderland
Stoke Therapeutics Stoke Therapeutics
STOK
$ 25.29 1.0 % $ 1.5 B usaUSA
Xencor Xencor
XNCR
$ 29.85 18.55 % $ 2.22 B usaUSA
Annexon Annexon
ANNX
$ 3.71 -1.18 % $ 575 M usaUSA
Can-Fite BioPharma Ltd. Can-Fite BioPharma Ltd.
CANF
$ 1.77 -0.56 % $ 2.91 M israelIsrael
Incyte Corporation Incyte Corporation
INCY
$ 113.32 -2.07 % $ 22.1 B usaUSA
Mesoblast Limited Mesoblast Limited
MESO
$ 12.44 1.3 % $ 15 B australiaAustralia
MeiraGTx Holdings plc MeiraGTx Holdings plc
MGTX
$ 9.17 -0.43 % $ 738 M usaUSA
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
VRTX
$ 513.55 -1.98 % $ 131 B usaUSA
Altimmune Altimmune
ALT
$ 2.07 -2.36 % $ 182 M usaUSA
Seagen Seagen
SGEN
- - $ 42.2 B usaUSA
Arcturus Therapeutics Holdings Arcturus Therapeutics Holdings
ARCT
$ 9.85 0.1 % $ 270 M israelIsrael
Arcutis Biotherapeutics Arcutis Biotherapeutics
ARQT
$ 31.72 1.67 % $ 4.04 B usaUSA
Assembly Biosciences Assembly Biosciences
ASMB
$ 19.86 0.1 % $ 223 M usaUSA
Oncternal Therapeutics Oncternal Therapeutics
ONCT
- -24.12 % $ 1.56 M usaUSA
ALX Oncology Holdings ALX Oncology Holdings
ALXO
$ 1.14 -2.99 % $ 61.2 M usaUSA
Iterum Therapeutics Iterum Therapeutics
ITRM
- - $ 591 K irlandaIrlanda
Applied Genetic Technologies Corporation Applied Genetic Technologies Corporation
AGTC
- - $ 26.5 M usaUSA
Achieve Life Sciences Achieve Life Sciences
ACHV
$ 6.58 1.36 % $ 287 M usaUSA
Ascendis Pharma A/S Ascendis Pharma A/S
ASND
$ 245.73 0.97 % $ 14.9 B danmarkDanmark
Alpine Immune Sciences Alpine Immune Sciences
ALPN
- - $ 2.17 B usaUSA
Crinetics Pharmaceuticals Crinetics Pharmaceuticals
CRNX
$ 84.95 0.13 % $ 7.99 B usaUSA
Concert Pharmaceuticals Concert Pharmaceuticals
CNCE
- - $ 401 M usaUSA
ImmunoGen ImmunoGen
IMGN
- - $ 7.92 B usaUSA
Vascular Biogenics Ltd. Vascular Biogenics Ltd.
VBLT
- -8.77 % $ 12.4 M israelIsrael
Histogen Histogen
HSTO
- 31.6 % $ 2.12 M usaUSA
Berkeley Lights Berkeley Lights
BLI
- -7.31 % $ 87 M usaUSA
Cidara Therapeutics Cidara Therapeutics
CDTX
- - $ 1.41 B usaUSA
Aurinia Pharmaceuticals Aurinia Pharmaceuticals
AUPH
$ 16.98 0.71 % $ 2.28 B canadaCanada
Denali Therapeutics Denali Therapeutics
DNLI
$ 18.52 0.6 % $ 3.2 B usaUSA
Clovis Oncology Clovis Oncology
CLVS
- -7.23 % $ 13 M usaUSA
Kaleido Biosciences Kaleido Biosciences
KLDO
- -3.69 % $ 12.4 M usaUSA
Annovis Bio Annovis Bio
ANVS
$ 0.94 -4.77 % $ 19.3 M usaUSA
Axon Enterprise Axon Enterprise
AXON
$ 418.83 -0.37 % $ 32.7 B usaUSA